Skip to main content
SpringerLink
Log in

Clinical Strategies for Developing Next-Generation Cancer Precision Medicines

  • Chapter
  • First Online:
Essentials of Bioinformatics, Volume II

  • 1266 Accesses

Abstract

The clinical development of EGFR inhibitors for non-small cell lung cancer is one of the greatest examples of precision medicine. The three generations of different EGFR inhibitors highlight the growing knowledge and implementation of genetic information into clinical thinking and hypotheses, the testing of these hypotheses in clinical development and, ultimately the acceptance of such targeted therapy as valuable transformational clinical tools. As each generational EGFR-inhibitor therapy is tested in the clinic, the responses of patients together with their individual genomic information provides the stage for the next-generational clinical development of this class of drugs. Non-small cell lung cancer behaves classically like most cancers, and in due time, responding patients will inevitably develop resistance to the targeted therapy. Using a broad range of disease biology, genetic dissection and clever chemistry, the generational clinical development of EGFR inhibitors for non-small cell lung cancer is one of the most inspiring and motivational accounts of how precision medicine is transforming healthcare worldwide.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Castellanos EH, Horn L (2015) Generations of epidermal growth factor receptor tyrosine kinase inhibitors: perils and progress. Curr Treat Options in Oncol 16:51

    Article  Google Scholar 

  • Ding PN, Lord SJ, Gebski V, Links M, Bray V, Gralla RJ, Yang JC, Lee CK (2017) Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: a meta-analysis of clinical trials of gefitinib, erlotinib, and afatinib in advanced EGFR-mutated non-small cell lung cancer. J Thorac Oncol 12(4):633–643

    Article  Google Scholar 

  • Douillard J, Hirsch V, Mok TS et al (2008) Molecular and clinical subgroup analyses from a phase III trial comparing gefitinib with docetaxel in previously treated non-small cell lung cancer (INTEREST). J Clin Oncol 26(suppl):8001

    Article  Google Scholar 

  • Dungo RT, Keating GM (2013) Afatinib: first global approval. Drugs 73:1503–1515

    Article  CAS  Google Scholar 

  • Fukuoka M, Yano S, Giaccone G et al (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 21:2237–2246

    Article  CAS  Google Scholar 

  • Fukuoka M, Wu Y-L, Thongprasert S, Sunpaweravong P, Leong S-S, Sriuranpong V et al (2011) Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non–small-cell lung cancer in Asia (IPASS). J Clin Oncol 29:2866–2874

    Article  CAS  Google Scholar 

  • Grandis JR, Sok JC (2004) Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 102:37–46

    Article  CAS  Google Scholar 

  • Gray J, Haura E (2014) Update on third-generation EGFR tyrosine kinase inhibitors. Transl Lung Cancer Res 3:360–362

    CAS  PubMed  PubMed Central  Google Scholar 

  • Hirsch FR, Varella-Garcia M, Cappuzzo F (2009) Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene 28:S32–S37

    Article  CAS  Google Scholar 

  • Inukai M, Toyooka S, Ito S, Asano H, Ichihara S, Soh J, Suehisa H, Ouchida M, Aoe K, Aoe M, Kiura K, Shimizu N, Date H (2006) Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res 66(16):7854–7858

    Article  CAS  Google Scholar 

  • Kazandjian D, Blumenthal GM, Yuan WS, He K, Keegan P, Pazdur R (2016) FDA approval of gefitinib for the treatment of patients with metastatic EGFR mutation–positive non–small cell lung cancer. Clin Cancer Res 22:1307–1312

    Article  CAS  Google Scholar 

  • Kim ES, Hirsh V, Mok T et al (2008) Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372:1809–1818

    Article  CAS  Google Scholar 

  • Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352(8):786–792

    Article  CAS  Google Scholar 

  • Kris MG, Natale RB, Herbst RS et al (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290:2149–2158

    Article  CAS  Google Scholar 

  • Lemmon MA, Schlessinger J (2010) Cell signalling by receptor tyrosine kinases. Cell 141:1117–1134

    Article  CAS  Google Scholar 

  • Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139

    Article  CAS  Google Scholar 

  • Merrick D, Kittelson J, Wintherhalder R, Kotantoulos G, Ingeberg S, Keith RL et al (2006) Analysis of c-ErbB1/epidermal growth factor receptor and c-ErbB2/HER-2 expression in bronchial dysplasia: evaluation of potential targets for chemoprevention of lung cancer. Clin Cancer Res 12:2281–2288

    Article  CAS  Google Scholar 

  • Mok TS et al (2009) Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957

    Article  CAS  Google Scholar 

  • Mok TS et al (2017) Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer. N Engl J Med 376:629–640

    Article  CAS  Google Scholar 

  • Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500

    Article  CAS  Google Scholar 

  • Pao W, Chmielecki J (2010) Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 10:760–774

    Article  CAS  Google Scholar 

  • Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L et al (2004) EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306–13311

    Article  CAS  Google Scholar 

  • Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2(3):e73

    Article  Google Scholar 

  • Pérez-Soler R (2004a) Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer. Clin Lung Cancer 6(Suppl 1):S20–S23

    Article  Google Scholar 

  • Pérez-Soler R (2004b) The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer. Clin Cancer Res 10:4238s–4240s

    Article  Google Scholar 

  • Pérez-Soler R, Chachoua A, Hammond LA et al (2004) Determinants of tumor response and survival with erlotinib in patients with non—small-cell lung cancer. J Clin Oncol 22:3238–3247

    Article  Google Scholar 

  • Posner I, Engel M, Gazit A, Levitzki A (1994) Kinetics of inhibition by tyrphostins of the tyrosine kinase activity of the epidermal growth factor receptor and analysis by a new computer program. Mol Pharmacol 45:673–683

    CAS  PubMed  Google Scholar 

  • Reck M et al (2010) Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment Study. J Thorac Oncol 5:1616–1622

    Article  Google Scholar 

  • Salomon DS, Brandt R, Ciardiello F, Normanno N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183–232

    Article  CAS  Google Scholar 

  • Sznol M (2010) Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype? Curr Opin Investig Drugs 11:1340

    PubMed  Google Scholar 

  • Walter AO, Sjin RT, Haringsma HJ, Ohashi K, Sun J, Lee K et al (2013) Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov 3:1404–1415

    Article  CAS  Google Scholar 

  • Wang S, Song Y, Yan F, Liu D (2016) Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors. Front Med 10(4):383–388

    Article  Google Scholar 

  • Zhou W, Ercan D, Chen L, Yun CH, Li D, Capelletti M et al (2009) Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462:1070–1074

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Life Science Expert at PA Consulting Ltd, 10 Bressenden Place, London, SW1E 5DN, UK

    Chee Gee See

  2. CGS Precision Medicine Consultancy, 5 Broadwater Avenue, Letchworth Garden City, Hertfordshire, UK

    Chee Gee See

Authors
  1. Chee Gee See
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chee Gee See .

Editor information

Editors and Affiliations

  1. Princess Al-Jawhara Center of Excellence in Research of Hereditary Disorders, Department of Genetic Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia

    Noor Ahmad Shaik

  2. Princess Dr. Najla Bint Saud Al-Saud Center for Excellence Research in Biotechnology, Department of Biological Sciences, King Abdulaziz University, Jeddah, Saudi Arabia

    Khalid Rehman Hakeem

  3. Princess Al-Jawhara Center of Excellence in Research of Hereditary Disorders, Department of Genetic Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia

    Babajan Banaganapalli

  4. Princess Al-Jawhara Center of Excellence in Research of Hereditary Disorders, Department of Genetic Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia

    Ramu Elango

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

See, C.G. (2019). Clinical Strategies for Developing Next-Generation Cancer Precision Medicines. In: Shaik, N., Hakeem, K., Banaganapalli, B., Elango, R. (eds) Essentials of Bioinformatics, Volume II. Springer, Cham. https://doi.org/10.1007/978-3-030-18375-2_7

Download citation

Publish with us

Policies and ethics

Search

Navigation